Q2 2025 Management View Marcus A. Lemonis, Executive Chairman and Principal Executive Officer, highlighted the company’s focus on operational discipline and delivery against key metrics, stating the ...

Blueprint shareholders will also receive one non-tradeable contingent value right, which will pay the holder $2 and $4 per right for future development and regulatory milestones for BLU-808, which ...

Quantum BioPharma Ltd. announced its plan to issue a special dividend in the form of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares, on a 1:1 basis.

Find the latest Gen Digital Inc. Contingent Value Rights (GENVR) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.

XenoTherapeutics has agreed to acquire Essa Pharma in a deal that is structured and financed by biotechnology royalty aggregator XOMA Royalty.

Regulus Therapeutics shareholders will also receive a so-called contingent value right, which entitles them to a further $900 million if regulatory approval is secured for farabursen, which seeks ...